Rheumatoid Arthritis Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

DelveInsight's "Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of rheumatoid arthritis, historical and forecasted epidemiology as well as the Rheumatoid arthritis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Unlock key insights into the Rheumatoid Arthritis Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Rheumatoid Arthritis Therapeutics Market Outlook- https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Rheumatoid Arthritis Market Report
• In April 2025, Immunovant Sciences GmbH announced a study consists of several periods. During the Screening Period (5 weeks) participants will undergo screening procedures to determine eligibility. In Period 1 (Open-Label Treatment), all eligible participants will receive open-label treatment with IMVT-1402 at a dose of 600 mg subcutaneous (SC) once weekly (QW) for 16 weeks.
• In April 2025, Eli Lilly and Company organized a study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis with inadequate response to a least one biologic disease-modifying antirheumatic drug (bDMARD)or targeted synthetic disease-modifying antirheumatic drug (tsDMARD).
• In April 2025, Sanofi conducted Phase 2 study, randomized, double-blind, placebo controlled, 5-arm, international, multicenter, 12-week proof of concept, dose finding study. It is designed to assess efficacy and safety of treatment with SAR441566 for 12 weeks. It will be conducted in male and female adult participants with moderate-to-severe rheumatoid arthritis (RA) not adequately controlled on methotrexate (MTX) and biologic/targeted synthetic disease modifying anti-rheumatic drug (DMARD) naive.
• Among the 7MM, the US accounted for the highest prevalent cases of rheumatoid arthritis in 2023, with around 1,430,000 cases were diagnosed with rheumatoid arthritis. Moreover, these cases are expected to increase during the forecast period.
• Amongst EU4 and the UK, the diagnosed prevalent cases of rheumatoid arthritis were highest in Germany, while the lowest number of cases was in France in 2023.
• In the US, the total age-specific prevalent cases of rheumatoid arthritis were highest in the age group for 55-64 years in 2023.
• The leading Rheumatoid Arthritis Companies such as R-Pharm, Taisho Pharmaceuticals, GlaxoSmithKline, Aclaris Therapeutics, Bristol Myers Squibb, Eli Lilly, Taiho Pharmaceutical, Cyxone, Gilead Sciences, Kiniksa Pharmaceuticals, Istesso, Applied Molecular Transport, Horizon Therapeutics, Genosco (Oscotec), Hope Biosciences, Abivax, Mesoblast, Pfizer, Akros Pharma/Japan Tobacco, Pfizer/Philogen, AbbVie, Pfizer, and SynAct Pharma and others.
• Promising Rheumatoid Arthritis Pipeline Therapies such as BMS-582949, etanercept, Filgotinib Maleate, Hemay007 800 mg, IMVT-1402, TLL-018, CPL409116, LY3541860 and others.

Stay ahead in the competitive landscape of the Rheumatoid Arthritis Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Rheumatoid Arthritis Treatment Market Size- https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Rheumatoid Arthritis Epidemiology Segmentation in the 7MM
• Total Rheumatoid Arthritis Prevalent cases
• Rheumatoid Arthritis Diagnosed Prevalent cases
• Rheumatoid Arthritis Gender-specific Prevalent cases
• Rheumatoid Arthritis Age-specific Prevalent cases
• Rheumatoid Arthritis Severity-specific Prevalent cases
• Rheumatoid Arthritis Patients on targeted therapies
• Rheumatoid Arthritis Line-Wise Treated Cases

Download the report to understand which factors are driving Rheumatoid Arthritis epidemiology trends @ Rheumatoid Arthritis Prevalence- https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Rheumatoid Arthritis Marketed Drugs
• OLUMIANT (barticinib): Eli Lilly and Company/Incyte Corporation
OLUMIANT is an immunosuppressant that is indicated for use in inflammatory and autoimmune diseases, or in other terms, it is defined as a Janus kinase (JAK) inhibitor used to treat adults with moderate to severe RA who have not responded well enough to or could not tolerate at least one medicine called a tumor necrosis factor (TNF) antagonist. This novel agent achieved its approval on the basis of well-conducted late-stage clinical trials in countries like the US, Europe, and Japan. OLUMIANT is approved with a Boxed Warning for the risk of serious infections, malignancies, and thrombosis. Currently, OLUMIANT is conducting a Phase II trial (NCT04870203) in combination with adalimumab in rheumatoid arthritis.

• RINVOQ (upadacitinib): AbbVie
RINVOQ- an AbbVie product is a prescription medicine used to treat adults with moderate to severe RA in whom methotrexate did not work well or could not be tolerated. In August 2019, AbbVie announced that the US FDA has approved RINVOQ for the treatment of adults with moderately to severely active RA who have had an inadequate response or intolerance to methotrexate.

Rheumatoid Arthritis Emerging Drugs
• Rabeximod (Rob 803): Cyxone
Rabeximod is an orally available drug with a unique mechanism of action that selectively targets the inflammatory macrophage, a type of white blood cell that is the central orchestrator of the inflammatory process that causes tissue destruction and clinical symptoms in rheumatoid arthritis. Rabeximod has been extensively studied in Phase I and Phase II clinical trials. Safety studies reveal a favorable safety profile compared to anti-rheumatoid arthritis drugs such as anti-TNFα monoclonal antibodies and oral JAK inhibitors.

• Imvotamab: IGM Biosciences
Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. It has 10 binding units for CD20, and it may successfully bind to CD20 expressing B cells with more power (avidity) compared to an IgG bispecific antibody with only one or two binding units for CD20. The company is currently evaluating Imvotamab in Phase-Ib trial for severe rheumatoid arthritis and mostly autoimmune diseases mediated by B-cells. Additionally, in vitro studies show that Imvotamab is significantly more effective than rituximab in depleting low CD20 expressing cells.

To learn more about Rheumatoid Arthritis Treatment guidelines, visit @ Rheumatoid Arthritis Market Drivers and Barriers- https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Rheumatoid Arthritis Companies
R-Pharm, Taisho Pharmaceuticals, GlaxoSmithKline, Aclaris Therapeutics, Bristol Myers Squibb, Eli Lilly, Taiho Pharmaceutical, Cyxone, Gilead Sciences, Kiniksa Pharmaceuticals, Istesso, Applied Molecular Transport, Horizon Therapeutics, Genosco (Oscotec), Hope Biosciences, Abivax, Mesoblast, Pfizer, Akros Pharma/Japan Tobacco, Pfizer/Philogen, AbbVie, Pfizer, and SynAct Pharma and others.

Rheumatoid Arthritis Market Outlook
Treatment of patients with RA aims to control pain and inflammation and, ultimately, the goal is remission or at least low disease activity. The FDA that can slow the course of the disease and improve the quality of life has approved scarcely any drugs. Therefore, the management of rheumatoid arthritis remains supportive and symptom-based. In recent years, research on new treatment strategies has increased, taking heed of monoclonal antibodies, small molecules, and others. There are limited approved drugs that slow disease progression by prolonging autonomy and increasing survival rates. Moreover, approved by the US FDA to treat rheumatoid arthritis, including OLUMIANT, RINVOQ, and ORENCIA.

Explore the dynamics of the Rheumatoid Arthritis Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Rheumatoid Arthritis Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Rheumatoid Arthritis Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Rheumatoid Arthritis Companies- R-Pharm, Taisho Pharmaceuticals, GlaxoSmithKline, Aclaris Therapeutics, Bristol Myers Squibb, Eli Lilly, Taiho Pharmaceutical, Cyxone, Gilead Sciences, Kiniksa Pharmaceuticals, Istesso, Applied Molecular Transport, Horizon Therapeutics, Genosco (Oscotec), Hope Biosciences, Abivax, Mesoblast, Pfizer, Akros Pharma/Japan Tobacco, Pfizer/Philogen, AbbVie, Pfizer, and SynAct Pharma and others.
• Rheumatoid Arthritis Pipeline Therapies- BMS-582949, etanercept, Filgotinib Maleate, Hemay007 800 mg, IMVT-1402, TLL-018, CPL409116, LY3541860 and others.
• Rheumatoid Arthritis Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Rheumatoid Arthritis Unmet Needs, KOL's views, Analyst's views, Rheumatoid Arthritis Market Access and Reimbursement

Table of Contents
1 Key Insights
2 Report Introduction
3 Executive Summary
4 Key Events
5 Epidemiology and Market Forecast Flow Methodology
6 Rheumatoid Arthritis Market Overview at a Glance
7 Disease Background and Overview
8 Treatment and Management of Rheumatoid Arthritis
9 Guidelines for Management of Rheumatoid Arthritis with Synthetic and Biological Disease-modifying Antirheumatic Drugs (European Alliance of Associations for Rheumatology)
10 Treatment Guidelines for RA (National Institute for Health and Care Excellence)
11 Guidelines for Management of RA (American College of Rheumatology)
12 Clinical Practice Guidelines for RA (Italian Society for Rheumatology)
13 Guidelines for the use of methotrexate in patients with Rheumatoid Arthritis (Japan College of Rheumatology (JCR))
14 Treatment Algorithm
15 Epidemiology and Patient Population of 7MM
16 Patient Journey
17 Key Endpoints in Rheumatoid Arthritis Clinical Trials
18 Marketed Drugs
19 Emerging Drugs
20 Rheumatoid arthritis: 7MM Market Analysis
21 Unmet Needs
22 SWOT Analysis
23 Market Access and Reimbursement of Rheumatoid Arthritis Therapies
24 KOL Views
25 Appendix
26 DelveInsight Capabilities
27 Disclaimer
28 About DelveInsight

List of Top Selling Market Research Reports in 2025

radial artery compression device market- https://www.delveinsight.com/report-store/transradial-access-products-market
vital sign monitors devices market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
cone rod dystrophy market- https://www.delveinsight.com/report-store/cone-rod-dystrophy-market
opioid-related disorders market- https://www.delveinsight.com/report-store/opioid-related-disorders-market
adeno associated viruses aav gene therapy market- https://www.delveinsight.com/report-store/adeno-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight
cystic fibrosis market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
scoliosis market - https://www.delveinsight.com/report-store/scoliosis-market
antibody drug conjugate market - https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
methicillin-resistant staphylococcus aureus infection market- https://www.delveinsight.com/report-store/methicillin-resistant-staphylococcus-aureus-mrsa-market
pediatric brain tumor market- https://www.delveinsight.com/report-store/pediatric-brain-tumors-market
smoking cessation market- https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-addiction-market
uterine fibroids market- https://www.delveinsight.com/report-store/uterine-leiomyoma-uterine-fibroids-market
atopic dermatitis market- https://www.delveinsight.com/report-store/atopic-dermatitis-market
cardiogenic shock market- https://www.delveinsight.com/report-store/early-cardiogenic-shock-cs-market
chemotherapy induced neutropenia market- https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-market
CXCR inhibitors market- https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
friedreich's ataxia market- https://www.delveinsight.com/report-store/friedreichs-ataxia-market
herpes labialis market- https://www.delveinsight.com/report-store/herpes-labialis-market
herpes zoster market- https://www.delveinsight.com/report-store/herpes-zoster-market
somatotropin deficiency market- https://www.delveinsight.com/report-store/growth-hormone-deficiency-ghd-market
spinal trauma devices market- https://www.delveinsight.com/report-store/trauma-devices-market
tcr therapy market- https://www.delveinsight.com/report-store/tcr-therapy-market
transcatheter heart valve replacement devices market- https://www.delveinsight.com/report-store/transcatheter-heart-valve-replacement-devices-market
atherosclerosis market- https://www.delveinsight.com/report-store/atherosclerotic-cardiovascular-disease-ascvd-market
carcinoid syndrome market- https://www.delveinsight.com/report-store/carcinoid-tumor-market
cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
chronic heart failure market- https://www.delveinsight.com/report-store/heart-failure-market
chronic venous ulceration market- https://www.delveinsight.com/report-store/chronic-venous-ulceration-market
diabetic wound market- https://www.delveinsight.com/report-store/diabetic-wounds-market
hypertrophic cardiomyopathy market- https://www.delveinsight.com/report-store/hypertrophic-cardiomyopathy-market
langerhans cell histiocytosis market- https://www.delveinsight.com/report-store/langerhans-cell-histiocytosis-market
liver fibrosis market- https://www.delveinsight.com/report-store/liver-fibrosis-market
membranous nephropathy market- https://www.delveinsight.com/report-store/idiopathic-membranous-nephropathy-imn-market
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
pelvic organ prolapse market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
plaque modification devices market- https://www.delveinsight.com/report-store/plaque-modification-devices-market
primary ciliary dyskinesia market- https://www.delveinsight.com/report-store/primary-ciliary-dyskinesia-market
psoriasis vulgaris market- https://www.delveinsight.com/report-store/psoriasis-vulgaris-market
radiodermatitis market- https://www.delveinsight.com/report-store/radiation-dermatitis-market
ranibizumab biosimilars market- https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
seasonal allergic rhinitis market- https://www.delveinsight.com/report-store/allergic-rhinitis-market
sly syndrome market- https://www.delveinsight.com/report-store/sly-syndrome-market
social anxiety disorder market- https://www.delveinsight.com/report-store/social-anxiety-disorder-market
soft tissue sarcoma with lung metastasis market- https://www.delveinsight.com/report-store/soft-tissue-sarcoma-with-lung-metastases-market
surgical bleeding market- https://www.delveinsight.com/report-store/surgical-bleeding-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.